Yahoo Web Search

Search results

  1. People also ask

  2. Apr 4, 2024 · COVID Variant JN. 1. Currently, COVID JN. 1 is the most prevalent variant. According to the Centers for Disease Control and Prevention (CDC), as of March 2024, this variant accounted for over 95%...

  3. 5 days ago · As of 3 March 2023, ECDC has de-escalated BA.2, BA.4 and BA.5 from its list of SARS-CoV-2 variants of concern (VOC), as these parental lineages are no longer circulating. ECDC will continue to categorise and report on specific SARS-CoV-2 sub-lineages in circulation that are relevant to the epidemiological situation.

  4. Mar 31, 2024 · From May 2021 onwards, WHO began assigning simple, easy-to-say labels for key variants. Considerable progress has been made in establishing and strengthening a global system to detect signals of potential VOIs or VOCs and rapidly assess the risk posed by SARS-CoV-2 variants to public health.

  5. Apr 17, 2024 · COVID-19 Variant Update. 17 April, 2024. As of April 17, 2024, the SARS-CoV-2 Omicron variant JN.1 has very high prevalence in the United States, with CDC Nowcast projections estimating JN.1 to account for more than 95% of all COVID-19 illnesses in the US.

  6. Apr 19, 2024 · The CDC says the updated vaccines should also work against currently circulating variants of the SARS-CoV-2 virus—many of which descended from, or are related to, the XBB strain. The vaccine is also expected to protect against JN.1, the current dominant strain in the U.S.

    • kathy.katella-cofrancesco@yale.edu
  7. Apr 12, 2024 · In this edition, we include: • The COVID-19 epidemiological update at the global and regional levels. • An update on hospitalizations and ICU admissions. • An update on the SARS-CoV-2 variants of interest (VOI) and variants under monitoring (VUM).

  8. 1 day ago · The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants. As the virus is expected to continue to evolve from JN.1, the TAG-CO-VAC advises the use of a monovalent JN.1 lineage as the antigen in future formulations of COVID-19 vaccines.

  1. People also search for